1. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
- Author
-
de Vries PJ, van der Meide WF, Godfried MH, Schallig HD, Dinant HJ, and Faber WR
- Subjects
- Administration, Oral, Antiprotozoal Agents pharmacokinetics, Humans, Leishmaniasis, Cutaneous complications, Leishmaniasis, Visceral complications, Male, Middle Aged, Phosphorylcholine administration & dosage, Phosphorylcholine pharmacokinetics, Psoriasis complications, Psoriasis drug therapy, Self-Sustained Sequence Replication methods, Treatment Outcome, Antiprotozoal Agents administration & dosage, Leishmaniasis, Cutaneous drug therapy, Leishmaniasis, Visceral drug therapy, Phosphorylcholine analogs & derivatives
- Abstract
A male patient with psoriatic arthritis and visceral Leishmania infantum infection was treated with oral miltefosine 50 mg three times a day for 4 weeks at the Academic Medical Center, Amsterdam, The Netherlands. Miltefosine plasma concentrations were measured with liquid chromatography/mass spectrometry. The parasite load was followed by quantitative nucleic acid sequence-based amplification (QT-NASBA) assay in blood. Miltefosine elicited a prompt therapeutic effect. After an initial worsening of symptoms and an increase of QT-NASBA values during the first week, recovery was rapidly achieved. QT-NASBA values declined exponentially and were negative after 6 weeks. Miltefosine plasma concentrations continued to accumulate during the 4 weeks of treatment. The terminal elimination half-life was 14.8 days.
- Published
- 2006
- Full Text
- View/download PDF